✦ LIBER ✦

First-line chemotherapy rechallenge after relapse in small cell lung cancer

✍ Scribed by Mark Vincent; Barrie Evans; Ian Smith

Publisher: Springer
Year: 1988
Tongue: English
Weight: 345 KB
Volume: 21
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00262737

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Non-small-cell lung cancer progression a

Non-small-cell lung cancer progression after first-line chemotherapy

✍ Primo N. Lara; Derick H. M. Lau; David R. Gandara 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 212 KB

Multifocal relapse after concurrent chem

Multifocal relapse after concurrent chemotherapy and radiotherapy of small cell lung cancer

✍ Dr. Harvey Kreisman; Norman Wolkove; Carol Cohen; Israel Winkler; Narayanan P. T 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 327 KB 👁 2 views

Second–line chemotherapy for non—small–c

Second–line chemotherapy for non—small–cell lung cancer

✍ Frank V. Fossella 📂 Article 📅 2000 🏛 Current Science Inc. 🌐 English ⚖ 225 KB

Multiple myeloma emerging after chemothe

Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer

✍ Spyridon Marinopoulos; Lamprini Skorda; Stylianos Karatapanis; Antonis Rasidakis 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 114 KB

Erlotinib as salvage treatment after fai

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

✍ Matthew K. Wong; Alvis I. Lo; Bing Lam; W. K. Lam; Mary S. Ip; James C. Ho 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 197 KB

Second-line treatments after first-line

Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer

✍ Jenn-Yu Wu; Jin-Yuan Shih; Chih-Hsin Yang; Kuan-Yu Chen; Chao-Chi Ho; Chong-Jen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 236 KB

## Abstract Gefitinib is effective as first‐line therapy for advanced nonsmall cell lung cancer (NSCLC). However, after failure of gefitinib, it is unknown whether any second‐line regimens could lead to better outcomes. To study the influence of different second‐line antitumor regimens on the outco